Neuphoria Therapeutics Inc. (NEUP)
| Market Cap | 8.57M |
| Revenue (ttm) | 662,715 |
| Net Income (ttm) | -8.21M |
| Shares Out | 1.76M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,613 |
| Open | 4.950 |
| Previous Close | 5.050 |
| Day's Range | 4.817 - 5.240 |
| 52-Week Range | 2.124 - 15.720 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 21.00 (+330.33%) |
| Earnings Date | Feb 14, 2025 |
About NEUP
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NEUP stock is "Strong Buy" and the 12-month stock price forecast is $21.0.
News
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment tr...
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangemen...